tradingkey.logo

Evogene Ltd

EVGN
View Detailed Chart
1.080USD
-0.020-1.82%
Close 02/06, 16:00ETQuotes delayed by 15 min
9.41MMarket Cap
LossP/E TTM

Evogene Ltd

1.080
-0.020-1.82%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.82%

5 Days

+6.93%

1 Month

-6.09%

6 Months

-13.60%

Year to Date

-1.82%

1 Year

-30.77%

View Detailed Chart

TradingKey Stock Score of Evogene Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Evogene Ltd's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 123 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evogene Ltd's Score

Industry at a Glance

Industry Ranking
123 / 392
Overall Ranking
260 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Evogene Ltd Highlights

StrengthsRisks
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 408.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.51M.
Undervalued
The company’s latest PE is -7.87, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.82.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
2.500
Target Price
+127.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evogene Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Evogene Ltd Info

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Ticker SymbolEVGN
CompanyEvogene Ltd
CEOEmber (Brian)
Websitehttps://evogene.com/
KeyAI